Robin M Daly, Nicole Petrass, Shona Bass, and Caryl A Nowson

The skeletal benefits of calcium- and vitamin D 3 fortified milk are sustained in older men after withdrawal of supplementation: an 18-mo follow-up study 1 3 Robin M Daly, Nicole Petrass, Shona Bass, and Caryl A Nowson ABSTRACT Background: In a previous 2-y randomized controlled trial, we showed that calcium- and vitamin D 3 fortified milk stopped or slowed bone loss at several clinically relevant skeletal sites in older men. Objective: The present study aimed to determine whether the skeletal benefits of the fortified milk were sustained after withdrawal of the supplementation. Design: One hundred nine men 50 y old who had completed a 2-y fortified milk trial were followed for an additional 18 mo, during which no fortified milk was provided. Bone mineral density (BMD) of the total hip, femoral neck, lumbar spine, and forearm was measured by using dual-energy X-ray absorptiometry. Results: Comparison of the mean changes from baseline between the groups (adjusted for baseline age, BMD, total calcium intake, and change in weight) showed that the net beneficial effects of fortified milk on femoral neck and ultradistal radius BMD at the end of the intervention (1.8% and %, respectively; P 0.01 for both) were sustained at 18-mo follow-up (P 0.05 for both). The nonsignificant between-group differences at the total hip (0.8%; P 0.17) also persisted at follow-up (0.7%; P 0.10), but there were no lasting benefits at the lumbar spine. The average total dietary calcium intake in the milk supplementation group at follow-up approximated recommended amounts for Australian men 50 y old (1000 mg/d) but did not differ significantly from that in the control subjects (1021 versus 890 mg/d). Conclusion: Supplementation with calcium- and vitamin D 3 fortified milk for 2 y may provide some sustained benefits for BMD in older men after withdrawal of supplementation. Am J Clin Nutr 2008;87:771 7. KEY WORDS Milk supplementation, fortified milk, supplement withdrawal, men, bone mineral density, osteoporosis INTRODUCTION Increasing or maintaining adequate intakes of dietary calcium and vitamin D is recognized as an important strategy for the prevention and management of osteoporosis. In both elderly men and women, numerous randomized controlled trials (RCTs) have shown that the combined use of calcium and vitamin D supplements can reduce secondary hyperparathyroidism, slow the rate of bone turnover, and attenuate or even prevent age-related bone loss (1 3). The greatest benefits of supplementation are generally observed in persons who adhere to the supplementation regimen (4) or who have low dietary calcium intakes, low circulating concentrations of serum 25-hydroxyvitamin D [25(OH)D], or both (5 7). In a recent 2-y RCT in men 50 y old, we found that daily supplementation with 400 ml low-fat, calcium- and vitamin D 3 enriched milk containing 1000 mg Ca and 800 IU vitamin D 3 was effective for increasing serum 25(OH)D, reducing parathyroid hormone (PTH) concentrations, and stopping or slowing the rate of bone loss at the femoral neck, total hip, and ultradistal radius (8). Whereas these findings support the use of a food-based approach to increase dietary calcium and vitamin D intakes to help maintain bone status or prevent age-related bone loss in older men, an important clinical question that remains to be answered is whether there are any residual skeletal benefits after withdrawal of supplementation. Numerous follow-up studies have investigated the residual effects of supplementation with calcium, vitamin D, or both or of milk supplementation on BMD in older adults, but the findings have been inconsistent and predominantly limited to older women (9 11). Therefore, the aim of the present study was to determine whether the skeletal benefits obtained after supplementation with calcium- and vitamin D 3 fortified milk were sustained 18 mo after withdrawal of the supplementation in ambulatory community-dwelling men 50 y old. We hypothesized that the rates of change in BMD would not differ significantly between the milk supplementation and control groups during the follow-up period. SUBJECTS AND METHODS Study design and subjects This study was an 18-mo follow-up to a 2-y RCT designed to assess the effects of calcium- and vitamin D 3 fortified milk on 1 From the Centre for Physical Activity and Nutrition Research, School of Exercise and Nutrition Sciences, Deakin University, Melbourne, Australia. 2 Supported by grants from the Geoffrey Gardiner Dairy Foundation and the Helen M Schutt Trust and by a National Health and Medical Research Council Career Development Award (to RMD and SB). 3 Reprints not available. Address correspondence to RM Daly, Centre for Physical Activity and Nutrition Research, School of Exercise and Nutrition Sciences, Deakin University, 221 Burwood Highway, Burwood, Melbourne, Australia 3125. E-mail: robin.daly@deakin.edu.au. Received July 3, 2007. Accepted for publication September 28, 2007. Am J Clin Nutr 2008;87:771 7. Printed in USA. 2008 American Society for Nutrition 771

772 DALY ET AL BMD in middle-aged and older men. In the initial 2-y intervention (8), 167 men aged 50y(x SD age: 61.9 7.7 y) were randomly allocated to either a calcium- and vitamin D 3 fortified milk group (milk supplementation group; n 85) or a usual-care control group (n 83). Men assigned to the fortified milk group were asked to consume daily 400 ml reduced-fat ( 1% fat) ultra-high-temperature (UHT) milk that contained 1000 mg Ca and 800 IU vitamin D 3. All participants enrolled in this study were healthy, ambulatory, community-dwelling white men who had a total hip, femoral neck, or lumbar spine BMD z score within 2 SDs. Participants were initially excluded if they had taken supplements of calcium ( 200 mg/d), vitamin D ( 200 IU/d), or both in the preceding 12 mo; had participated in regular highintensity resistance training in the previous 6 mo or participated in 150 min/wk of moderate- to high-impact weight-bearing exercise in the previous 6 mo; had a BMI 35; were lactose intolerant; consumed 4 alcoholic beverages/d; or had a history of osteoporotic fracture or medical disease or of the use of any medication known to affect bone metabolism. Of the 149 men who completed the original 2-y intervention, 109 (73%) completed the 18-mo follow-up evaluation: 55 (72%) from the milk supplementation group and 54 (74%) from the control group. The reasons for not attending the follow-up visit in the milk supplementation group were that the subject was not interested (n 12), had been diagnosed with cancer (n 2), could not be contacted (n 4), had moved away (n 2), or had died (n 1). For the control group, the main reasons were that the subject was not interested (n 13), had been diagnosed with cancer (n 2), could not be contacted (n 2), or had moved away (n 2). During the follow-up period, participants were not provided with the fortified milk, and they were not asked to avoid taking supplements that might have an affect on bone metabolism. At the completion of the 2-y intervention, all participants were informed of the results of the study and provided with a booklet outlining their individual results, including their changes in BMD. At baseline and at 24 mo, there were no significant differences in the subject characteristics (ie, age, anthropometry, diet, physical activity, or baseline BMD) between the men who did (n 109) and did not (n 58) attend the final follow-up visit. Written informed consent was obtained from all participants. The study was approved by the Deakin University Human Research Ethics Committee. Measurements To minimize the potential effects of seasonal variations on the key outcome measures, all testing for each data collection for both groups was completed within a 3-mo period, starting between April and June (which, in Australia, is from autumn to winter). Femoral neck, total hip, lumbar spine (L 2 L 4 ), ultradistal radius, and 33% radius BMD measurements were assessed by using dual-energy X-ray absorptiometry (DPX-L; Lunar Corp, Madison, WI) with DPX-L analysis software (version 4.7e; Lunar Corp). Patients were positioned for each scan according to standard procedures, and all follow-up scans were analyzed by using the manufacturer s scan-comparison mode. The short-term CV for repeated measurement in our laboratory ranged from 0.9% to 1.9% for the BMD measures. Quality control over the 42-mo study period was monitored by using the manufacturer s external spine phantom (CV: 0.65%). As described previously (8), height (in cm) was measured by using a stadiometer (Holtain Ltd, Crosswell, United Kingdom). Body weight (in kg) was assessed by using electronic scales that were correct to the nearest 0.1 kg (Seca GmbH, Hamburg, Germany). Body mass index (BMI; in kg/m 2 ) was calculated. At each visit, nutrient intakes were estimated from 3-d (2 weekdays and 1 weekend day) measured food diaries, with the option of weighing items, and intakes were analyzed by using FOOD- WORKS nutrient analysis software (version 4.0; Xyris Software, Brisbane, Australia). The Community Health Activities Model Program for Seniors physical activity survey (developed by the Institute for Health & Aging, University of California, San Francisco, and the Stanford Center for Research in Disease Prevention, Stanford University) was used to assess participation in recreational and organized physical activity (h weight-bearing exercise/wk) throughout the study (12). Information on the use of medication and supplements including calcium, vitamin D, and multivitamin supplementation and on alcohol consumption was obtained with the use of questionnaires and was confirmed by interview at each visit. The amount of milk consumed (glasses/d) was also determined from an interview-administered dairy-based food-frequency questionnaire at each time-point. At month 24, participants were asked not to include the calcium- and vitamin D fortified milk in their responses to this questionnaire. Statistical analysis Statistical analysis was conducted by using STATA statistical software (version 8.0; Stata Corp, College Station, TX). Baseline characteristics between the groups were compared by using independent t tests for continuous variables and chi-square tests for categorical variables. Pooled time series regression analysis for longitudinal data with random-effects models was used to analyze time, group, and interaction effects for all continuous variables (ie, anthropometry, physical activity, diet, and BMD) in the 109 men who completed the study. To compare the changes in BMD between the groups, results were analyzed after adjustment for baseline age, BMD, total calcium intake (or total calcium intake at month 42), and change in weight. The changes in BMD were expressed as the absolute and percentage changes from baseline or from the end of the 24-mo intervention. Betweengroup differences were calculated by subtracting the withingroup changes from baseline (or the follow-up) in the milk supplementation group from those in the control group. Generalized estimating equations (GEE modeling) with the logit link function (calcium and vitamin D supplementation use) and longitudinal ordinal regression (frequency of milk consumption) were used to test within-group changes and between-group differences in the change in each of these measures. All data are presented as means SDs or 95% CI unless stated otherwise. RESULTS The characteristics of the 109 men at baseline, at the end of the 2-y intervention (beginning of follow-up), and at the 18-mo follow-up are shown in Table 1. There were no differences in anthropometric measures, physical activity levels, or dietary habits between the 2 groups at baseline or at the end of the intervention (month 24) except that dietary calcium intakes were greater in the milk supplementation group than in the control group at both of these time-points; vitamin D and phosphorus intakes were also greater in the milk supplementation group than in the control group at month 24. This difference was due to the inclusion of the calcium- and vitamin D 3 fortified milk in the

RESIDUAL BENEFITS OF FORTIFIED MILK ON BMD IN MEN 773 TABLE 1 Age, anthropometric, physical activity, and dietary characteristics of the study participants at baseline and at the end of the intervention (month 24) and follow-up (month 42) for the milk supplementation and control groups 1 Characteristic and group Baseline (month 0) End of intervention (month 24) P for interaction (0 24 mo) End of follow-up (month 42) P for interaction (0 42 mo) Age (y) Milk 60.8 7.0 2 62.8 7.0 65.2 7.0 Control 61.9 7.6 63.9 7.6 0.22 65.4 7.6 0.06 Height (cm) Milk 175.3 7.6 175.4 7.5 175.1 7.8 Control 175.1 8.0 175.0 8.2 0.13 174.9 8.1 0.81 Weight (kg) Milk 80.0 12.2 80.9 13.1 79.6 12.6 3 Control 80.8 10.7 80.6 10.6 0.12 80.0 9.8 2 BMI (kg/m 2 ) Milk 25.9 3.0 26.2 3.3 25.9 3.1 Control 26.3 2.9 26.3 2.9 0.21 26.1 2.7 0.60 Weight-bearing exercise (h/wk) Milk 4.9 3.6 5.4 4.0 5.5 3.1 Control 5.7 5.6 5.2 3.7 0.16 4.4 3.4 0.06 Total energy intake (kj/d) Milk 9147 2534 9522 1955 8704 1890 4 Control 8384 2286 8777 1882 0.93 8336 1556 0.16 Protein (g) Milk 97 27 107 28 5 94 23 4 Control 93 23 98 20 0.45 92 25 2 Fat (g) Milk 77 30 76 21 72 24 Control 72 30 76 25 0.16 71 22 0.23 Protein (% of energy) Milk 18.1 2.9 19.4 3.7 5 19.0 3.3 Control 19.1 3.3 19.6 3.6 0.32 19.2 4.0 0.35 Fat (% of energy) Milk 30.4 6.7 30.1 5.9 30.7 5.9 Control 30.8 6.1 32.4 6.5 5 0.05 31.8 7.2 0.33 Carbohydrates (% of energy) Milk 47.7 8.3 46.7 7.3 45.7 7.2 5 Control 46.7 6.3 44.3 7.6 5 0.13 44.8 8.3 5 0.80 Dietary calcium (mg/d) Milk 1058 433 6 1749 469 7,8 976 306 4 Control 887 337 887 323 0.001 864 353 0.24 Dietary vitamin D ( g/d) Milk 1.7 1.8 19.4 8.5 7,8 2.2 4,5 Control 1.6 1.4 2.4 2.1 9 0.001 2.3 2.2 0.94 Phosphorus (mg/d) Milk 1671 494 1947 542 7,8 1645 414 4 Control 1526 376 1614 366 0.05 1557 533 0.29 1 n 55 and 54 in milk supplementation and control groups, respectively. All dietary data (3-d food diaries) for the milk supplementation group at month 24 include fortified milk. Interaction terms represent the significance levels for the group-by-time interactions for the changes after 24 and 42 mo. 2 x SD (all such values). 3,4 Significant within-group change from month 24: 3 P 0.05, 4 P 0.001. 5,8,9 Significant within-group change from baseline (month 0): 5 P 0.05, 8 P 0.001, 9 P 0.01. 6,7 Significantly different from controls: 6 P 0.05, 7 P 0.001. 24-mo dietary analysis. During the follow-up period, total energy, protein (in g), dietary and total calcium, and vitamin D and phosphorus intakes decreased significantly from the month 24 values in the milk supplementation group (Table 1). The mean reduction in dietary calcium and vitamin D was 801 mg/d and 17.6 g/d, respectively. There were no changes in any of the dietary variables in the control group from month 24 to month 42. Similarly, at the end of the follow-up period, there were no significant differences between the milk supplementation and control groups with respect to any of the dietary variables. Physical activity levels remained unchanged in both groups throughout the study. Body weight decreased in the milk supplementation group during the follow-up (mean change: 1.2 kg; 95% CI, 0.07, 2.4 kg), but this change did not differ significantly from that in control subjects (mean change: 0.6 kg; 95% CI, 0.4, kg). There were no group time interactions for calcium or vitamin D supplement use or the frequency of milk consumption

774 DALY ET AL TABLE 2 Proportion of men by treatment group who used a calcium or vitamin D supplement (or both), total calcium and vitamin D intake (supplements plus diet), and the frequency of milk consumption at baseline and at the end of the intervention and follow-up periods Baseline (month 0) End of intervention (month 24) Follow-up (month 42) Characteristic Milk group (n 55) Control group (n 54) Milk group (n 55) Control group (n 54) P for interaction (0 24 mo) Milk group (n 55) Control group (n 54) P for interaction (0 42 mo) Calcium supplement use (%) 1 None 96.4 96.3 94.5 88.9 81.8 86.9 1 200 mg/d 3.6 3.7 5.5 7.4 11.0 5.6 200 600 mg/d 0.0 0.0 0.0 3.7 3.6 5.6 600 mg/d 0.0 0.0 0.0 0.0 0.43 3.6 1.9 0.67 Total calcium intake (mg/d) 2 1059 432 3 891 341 1752 470 4,5 916 383 0.001 1021 361 6,7 890 369 0.35 Vitamin D supplement use (%) 1 None 96.4 98.1 94.5 87.0 83.6 88.8 1 200 IU/d 3.6 1.9 5.5 9.3 16.4 7.4 201 400 IU/d 0.0 0.0 0.0 0.0 0.0 0.0 400 IU/d 0.0 0.0 0.0 3.7 0.14 0.0 3.8 0.84 Total vitamin D intake ( g/d) 2 1.9 2.0 1.7 1.4 19.7 8.5 4,5 4.2 6.4 5 0.001 3.1 2.4 7 3.3 3.9 8 0.74 Frequency of milk consumption (%) 9 Rarely or never 12.7 18.5 27.2 13.0 11.3 16.7 1 glass/d 47.3 27.8 38.2 38.8 47.2 35.2 1 2 glasses/d 25.5 37.0 27.3 35.2 28.3 33.3 2 glasses/d 14.5 16.7 7.3 13.0 0.17 13.2 14.8 0.73 1 The number of men who reported using calcium and vitamin D supplements increased significantly during the follow-up period (baseline to month 42) in both groups, P 0.05. 2 Total calcium and vitamin D intakes represent dietary and supplement intake. 3,4 Significantly different from controls: 3 P 0.05, 4 P 0.001. 5,8 Significant within-group change from baseline (month 0): 5 P 0.001, 8 P 0.05. 6 Nonsignificantly different from controls, P 0.10. 7 Significant within-group change from month 24, P 0.001. 9 One glass is equivalent to 225 ml. Frequency of milk consumption at month 24 in the milk supplementation group excludes the fortified milk used in this study. after 24 or 42 mo (Table 2). However, the number of men who reported using calcium and vitamin D supplements increased significantly from baseline to month 42 in both the milk supplementation and control groups (P 0.05 for both). However, at follow-up (month 42), there were no differences between the 2 groups in total calcium and vitamin D supplementation use (18.2% and 16.7%, respectively). Although dietary calcium decreased significantly (P 0.001) in the milk supplementation group from month 24 to month 42, there was a trend for total calcium intake (dietary plus supplemental) to be greater in the milk than in the control group at follow-up (P 0.10). Similarly, there was a greater trend for the men in the milk supplementation group than in the control group (69% and 51%, respectively; P 0.09) to have a total calcium intake at follow-up (month 42) greater than the current Australian estimated average requirement (EAR) of 840 mg/d for men 51 70 y old (13). The EAR represents the daily calcium intake estimated to meet the requirements of 50% of Australian men in that age range. However, milk drinking habits did not differ significantly between the groups in the present study at any time during the intervention (Table 2). At the end of the intervention (month 24), however, the proportion of men in the milk supplementation group who reported regularly consuming milk tended to decrease (P 0.051), which is likely to be due to the exclusion during follow-up of the fortified milk used throughout the intervention; the men were asked during the interviewer-administered FFQ not to include the fortified milk as part of their postintervention daily milk consumption. At follow-up (month 42), 41% of all men reported that they consumed 1 glass of milk/d, whereas 45% reported consuming 1 2 or 2 glasses/d. Consistent with our previous report (8), there were no differences in baseline BMD at any skeletal site between the milk supplementation and control groups (Table 3). The mean adjusted between-group differences in the changes from baseline to the end of the intervention (month 24) and through follow-up (42 mo), and also in the duration of the follow-up (month 24 month 42), by treatment group for the 109 men who completed the study are reported in Table 4. The mean TABLE 3 Baseline bone mineral density in the fortified milk and control groups 1 Skeletal site Milk group Control group P Femoral neck 0.939 0.115 2 0.950 0.103 0.60 Total hip 1.017 0.119 1.043 0.113 0.24 Lumbar spine 1.229 0.171 1.189 0.159 0.19 UD radius 0.416 0.057 0.407 0.051 0.41 33% radius 0.787 0.080 0.768 0.071 0.19 1 n 55 and 54 in the fortified milk and control groups, respectively. UD, ultradistal. 2 x SD (all such values).

RESIDUAL BENEFITS OF FORTIFIED MILK ON BMD IN MEN 775 TABLE 4 Net adjusted mean absolute and percentage differences (and 95% CIs) in the change in bone mineral density (BMD) from baseline between the milk supplementation and control groups after the intervention and follow-up periods 1 Adjusted net differences (milk control group) (95% CI) BMD Intervention (0 24 mo) Follow-up 24 42 mo 0 42 mo Femoral neck Absolute 0.018 (0.007, 0.029) 0.006 ( 0.016, 0.005) 0.013 (0.000, 0.025) Percentage 1.8 (0.7, 3.0) 0.4 (, 0.6) 1.4 (0.1, 2.7) P 0.01 0.77 0.05 Total hip Absolute 0.008 ( 0.004, 0.019) 0.002 ( 0.012, 0.007) 0.007 ( 0.005, 0.018) Percentage 0.8 ( 0.4, 1.9) 0.2 ( 1.1, 0.7) 0.7 ( 0.4, 1.8) P 0.17 0.86 0.10 Lumbar spine Absolute 0.012 ( 0.002, 0.028) 0.005 ( 0.018, 0.008) 0.000 ( 0.019, 0.018) Percentage 0.9 ( 0.3, 2.2) 0.4 (, 0.7) 0.1 ( 1.6, 1.4) P 0.15 0.95 0.92 UD radius Absolute 0.006 (0.002, 0.010) 0.000 ( 0.006, 0.005) 0.005 (0.000, 0.009) Percentage (, 2.4) 0.1 ( 1.4, 1.2) 1.1 (0.0, 2.2) P 0.01 0.80 0.05 33% radius Absolute 0.004 ( 0.003, 0.010) 0.002 ( 0.010, 0.005) 0.001 ( 0.005, 0.008) Percentage ( 0.3, 1.3) 0.4 ( 1.3, ) 0.2 ( 0.7, 1.0) P 0.26 0.22 0.71 1 The adjusted net absolute and percentage differences represent the between-group differences (milk minus control group) in the changes in BMD after adjustment for baseline age, BMD, and change in weight. The inclusion of baseline or 42-mo total calcium intake did not alter the results. P values represent the significance of the group-by-time interactions for the changes after adjustment for the above covariates. unadjusted within-group changes are shown in Figure 1. Consistent with our previous report that included the full data set (n 149) (8), there was a significant between-group difference in the change in BMD relative to baseline after the 24-mo intervention in favor of the milk supplementation group at both the femoral neck (1.8%) and ultradistal radius (%). In contrast, the between-group difference at the total hip and the trend toward a difference at the lumbar spine in favor of the milk supplementation group in our previous study did not persist in this cohort [net adjusted percentage difference: total hip, 0.8% (P 0.17); lumbar spine, 0.9% (P 0.15)]. During the follow-up period (month 24 month 42), there was a small, nonsignificant decrease in BMD in both groups at the total hip and femoral neck, but there were no significant betweengroup differences in the changes in BMD at any skeletal site. Analysis of the mean changes from baseline between the groups showed that the net benefits of the fortified milk on femoral neck and ultradistal radius BMD after the intervention were sustained at the 18-mo follow-up. Similar results were also observed at the total hip, but the between-group difference remained nonsignificant at follow-up (net adjusted percentage difference, 0.7%; P 0.10). At the lumbar spine, the nonsignificant (0.9%) beneficial effect of the fortified milk on BMD was lost at follow-up ( 0.1%). There were no between-group differences in the change in BMD at the 33% radius at any time. These results remained unchanged after the inclusion of total calcium intake at follow-up (month 42) as a covariate. Furthermore, there was no significant effect of supplementation use on the changes in BMD at any skeletal site during the follow-up period in either group. DISCUSSION In this study of ambulatory community-dwelling older men who had previously participated in a 2-y RCT of calcium- and vitamin D 3 fortified milk, we found that the 1.8% and % net beneficial effects of the fortified milk on BMD at the clinically important femoral neck and ultradistal radius were sustained 18 mo after the end of the intervention. The 0.8% nonsignificant between-group differences at the total hip in favor of the milk supplementation group after the intervention also persisted at follow-up (0.7%), but there were no remaining supplementrelated benefits at the lumbar spine. It is likely that the residual skeletal benefits of the fortified milk in the men in this study were due to the maintenance of habitual calcium intakes at or above the current EAR (and recommended dietary intakes) for Australian men 51 70 y old. Consistent with the findings from the present study, a recent follow-up study to a 2-y milk supplementation trial in postmenopausal Chinese women showed that the significant net beneficial effects of milk on lumbar spine and femoral neck BMD (1.2% and 1.7%, respectively) were maintained after a 21-mo follow-up (mean between-group difference: 1.3% and 1.9%, respectively) (10). In that study, the residual effects of the milk supplementation on BMD were attributed, at least partly, to the maintenance of a higher dietary calcium (and protein intake) in the milk supplementation group during the follow-up period. The mean total calcium intake of the women previously assigned to the milk supplementation group was 273 mg/d greater than that of the controls (768 and 495 mg/d, respectively). In contrast to these

776 DALY ET AL Percentage change from baseline (%) * A B Percentage change from baseline (%) 0 6 12 18 24 42 C 0 6 12 18 24 42 Intervention Follow-up Intervention Follow-up (mo) (mo) FIGURE 1. Mean ( SE) unadjusted percentage changes from baseline in femoral neck (A), total hip (B), lumbar spine (C), and ultradistal radius (D) bone mineral density (BMD) in 109 men who were randomly assigned to the calcium- and vitamin D 3 fortified milk (F) or control (E) group and then followed up after 18 mo with no supplementation. * Significant between-group difference from baseline (group time interaction) after adjustment for baseline age, BMD, total calcium intake (or total calcium intake at follow-up), and change in weight (P 0.05). * D findings, in the only previous calcium and vitamin D supplementation follow-up study to have included older men (it also included older women), Dawson-Hughes et al (9) reported that the supplement-related benefits to lumbar spine and femoral neck BMD were lost 2 y after the supplementation ended in the older men and women (aged 68 y), although there were some residual benefits to total-body BMD in the men. Dietary calcium intakes in the men in that study during the follow-up were 800 mg/d, which was considerably below the US National Academy of Sciences recommendation for dietary calcium of 1200 mg/d, and thus may have been inadequate to prevent bone loss. Contrary to these findings, the mean total calcium intake in the milk supplementation group at the end of the follow-up period in the present study was 1021 mg/d. Although this intake did not differ significantly from baseline values or from values in the control group at follow-up, which averaged 890 mg/d, it was greater than the current Australian EAR of 840 mg/d for men 51 70 y old (13). Therefore, it would appear that maintaining a habitual calcium intake that exceeds the EAR for older men may be sufficient to prevent bone loss after withdrawal of supplementation. It is also possible that the provision of calcium in food products may result in a more sustained effect on BMD than do supplements. Partially supporting this possibility, the findings from a study in older women showed that those who obtain calcium primarily from the diet or from both diet and supplements had greater BMD than did those who obtain calcium primarily from supplements (14). There is some evidence to suggest that participation in nutrition-based interventions, BMD screening, an educational program designed to optimize bone health, or all 3 may lead to long-term behavioral changes with regard to increasing dietary intakes of calcium, vitamin D, or both (10, 15 18). In the present study, however, we found that dietary calcium intakes; the use of supplements with calcium, vitamin D, or both; and daily milk consumption did not differ significantly between the 2 groups 18 mo after the intervention. Although there was a trend for total calcium intake (combined diet and supplement use) to be greater in the milk supplementation group than in the control group at follow-up, dietary calcium intakes did not change significantly in the milk supplementation group from baseline to follow-up. Thus, it would appear that participation in a long-term foodbased intervention trial does not significantly influence the dietary behaviors of older men with respect to the intake of dietary calcium. Partially supporting these findings, the results from a 2-y follow-up study to a calcium tablet or milk powder supplementation trial showed that older women were more likely to continue voluntarily taking a tablet than to use a skim-milk powder supplement to maintain calcium intakes (19).

RESIDUAL BENEFITS OF FORTIFIED MILK ON BMD IN MEN 777 Several factors may explain the lack of a significant difference in total or dietary calcium intakes between the groups at followup. First, all of the men in the present study were informed of the study findings, and they received their individual BMD results after the completion of the 2-y intervention. A similar approach was adopted by Dawson-Hughes et al (9), who also reported that both the mean dietary calcium intakes and the use of calcium or vitamin D supplements were no greater in the treatment group than in the control group 2 y after calcium or vitamin D supplementation. Second, it is possible that the measures we used to monitor daily intakes of calcium and milk (3-d food diaries and FFQ) were not sensitive enough to detect any significant between-group differences that may have existed at follow-up. Third, dietary data were collected only at the end of the follow-up period, which may not provide an accurate estimate of the dietary habits of the men throughout the 18-mo follow-up period. Whereas the strength of this study lies in its long-term followup, there were 2 main limitations. First, only 73% of the men who completed the 2-y intervention returned for follow-up testing. However, the characteristics of these men were no different from those of the larger cohort of 149 men who completed the intervention, and the study remained adequately powered to detect significant between-group differences in the change in BMD. For the 2-y intervention, the observed power to detect a significant net beneficial effect of 1.8% and % at the femoral neck and ultradistal radius, respectively, in favor of the milk supplementation group in this cohort of 109 men was 95% and 82%, respectively. At the end of the follow-up period (month 42), we had 91% and 71% power for the observed 1.4% and 1.1% net differences at these 2 sites. Second, we have no information on the possible mechanism(s) that could explain the sustained effects on BMD in the milk supplementation group. Continued suppression of PTH could reduce the rate of bone loss, and that change could have been achieved by maintenance of a calcium intake equivalent to current recommended intakes in this group, but we did not measure PTH at follow-up. It has also been proposed that the additional protein associated with increased milk consumption may result in an increase in circulating concentrations of insulin-like growth factor-1 (20), an important growth factor known to stimulate bone formation, which may also enhance periosteal apposition. However, it is unlikely that this would explain the sustained benefits for BMD in the milk supplementation group, because we have previously reported no effect of the fortified milk on the quantitative computed tomography derived total bone cross-sectional area at the midfemur (21). In conclusion, the results from this study indicate that calciumand vitamin D 3 fortified milk may provide a sustained benefit for BMD in older men, which may help to prevent the development of osteoporosis later in life. Although the underlying mechanism contributing to these long-term beneficial skeletal effects remains to be determined, it is likely to be related to the maintenance of habitual calcium intakes above the current Australian recommended requirements for middle-aged and older men, which may assist in slowing bone loss. However, further longterm follow-up studies are needed to determine whether there is a threshold intake for dietary calcium or vitamin D or both above or below which any supplement-related skeletal gains may be maintained. The authors responsibilities were as follows RMD (principal investigator), SB, and CAN: study concept and design; RD and NP: acquisition of data; RD and CAN: analysis and interpretation of the data; RD: drafting of the manuscript; and CAN, SB, and NP: critical revision of the manuscript. None of the authors had a personal or financial conflict of interest. REFERENCES 1. Baeksgaard L, Andersen KP, Hyldstrup L. Calcium and vitamin D supplementation increases spinal BMD in healthy, postmenopausal women. Osteoporos Int 1998;8:255 60. 2. Dawson Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 1997;337:670 6. 3. Meier C, Woitge HW, Witte K, Lemmer B, Seibel MJ. Supplementation with oral vitamin D 3 and calcium during winter prevents seasonal bone loss: a randomized controlled open-label prospective trial. J Bone Miner Res 2004;19:1221 30. 4. Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669 83. 5. Chapuy MC, Pamphile R, Paris E, et al. Combined calcium and vitamin D 3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 2002;13:257 64. 6. Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D 3 and calcium to prevent hip fractures in the elderly women. N Engl J Med 1992;327: 1637 42. 7. Grados F, Brazier M, Kamel S, et al. Effects on bone mineral density of calcium and vitamin D supplementation in elderly women with vitamin D deficiency. Joint Bone Spine 2003;70:203 8. 8. Daly RM, Brown M, Bass S, Kukuljan S, Nowson CA. Calcium and vitamin D 3 fortified milk reduces bone loss at clinically relevant skeletal sites in older men: a 2-year randomised controlled trial. J Bone Miner Res 2006;31:397 405. 9. Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of withdrawal of calcium and vitamin D supplements on bone mass in elderly men and women. Am J Clin Nutr 2000;72:745 50. 10. Ting GP, Tan SY, Chan SP, et al. A follow-up study on the effects of a milk supplement on bone mineral density of postmenopausal Chinese women in Malaysia. J Nutr Health Aging 2007;11:69 73. 11. Devine A, Dick IM, Heal SJ, Criddle RA, Prince RL. A 4-year follow-up study of the effects of calcium supplementation on bone density in elderly postmenopausal women. Osteoporosis Int 1997;7:23 8. 12. Harada ND, Chiu V, King AC, Stewart AL. An evaluation of three self-report physical activity instruments for older adults. Med Sci Sports Exerc 2001;33:962 70. 13. National Health and Medical Research Council. Nutrient reference values for Australia and New Zealand including recommended dietary intakes. Canberra, Australia: Commonwealth of Australia and New Zealand Government, 2006. 14. Napoli N, Thompson J, Civitelli R, Armamento-Villareal RC. Effects of dietary calcium compared with calcium supplements on estrogen metabolism and bone mineral density. Am J Clin Nutr 2007;85:1428 33. 15. Winzenberg T, Oldenburg B, Frendin S, De Wit L, Riley M, Jones G. The effect on behavior and bone mineral density of individualized bone mineral density feedback and educational interventions in premenopausal women: a randomized controlled trial. BMC Public Health 2006;6:12. 16. Wong SY, Lau EM, Lau WW, Lynn HS. Is dietary counselling effective in increasing dietary calcium, protein and energy intake in patients with osteoporotic fractures? A randomized controlled clinical trial. J Hum Nutr Diet 2004;17:359 64. 17. Cerulli J, Zeolla MM. Impact and feasibility of a community pharmacy bone mineral density screening and education program. J Am Pharm Assoc 2004;44:161 7. 18. Tussing L, Chapman-Novakofski K. Osteoporosis prevention education: behavior theories and calcium intake. J Am Diet Assoc 2005;105: 92 7. 19. Devine A, Prince RL, Bell R. Nutritional effect of calcium supplementation by skim milk powder or calcium tablets on total nutrient intake in postmenopausal women. Am J Clin Nutr 1996;64:731 7. 20. Heaney RP, McCarron DA, Dawson-Hughes B, et al. Dietary changes favorably affect bone remodeling in older adults. J Am Diet Assoc 1999;99:1228 33. 21. Daly RM, Bass S, Nowson C. Long-term effects of calcium-vitamin-d 3 fortified milk on bone geometry and strength in older men. Bone 2006; 39:946 53.